Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

Abstract EN

Objectives.

To evaluate the cost-effectiveness of etoricoxib (90 mg) relative to celecoxib (200/400 mg), and the nonselective NSAIDs naproxen (1000 mg) and diclofenac (150 mg) in the initial treatment of ankylosing spondylitis in Norway.

Methods.

A previously developed Markov state-transition model was used to estimate costs and benefits associated with initiating treatment with the different competing NSAIDs.

Efficacy, gastrointestinal and cardiovascular safety, and resource use data were obtained from the literature.

Data from different studies were synthesized and translated into direct costs and quality adjusted life years by means of a Bayesian comprehensive decision modeling approach.

Results.

Over a 30-year time horizon, etoricoxib is associated with about 0.4 more quality adjusted life years than the other interventions.

At 1 year, naproxen is the most cost-saving strategy.

However, etoricoxib is cost and quality adjusted life year saving relative to celecoxib, as well as diclofenac and naproxen after 5 years of follow-up.

For a willingness-to-pay ceiling ratio of 200,000 Norwegian krones per quality adjusted life year, there is a >95% probability that etoricoxib is the most-cost-effective treatment when a time horizon of 5 or more years is considered.

Conclusions.

Etoricoxib is the most cost-effective NSAID for initiating treatment of ankylosing spondylitis in Norway.